9BSV image
Entry Detail
PDB ID:
9BSV
EMDB ID:
Keywords:
Title:
EBOV GP/Nanosota-EB2 complex
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2024-05-13
Release Date:
2024-12-18
Method Details:
Experimental Method:
Resolution:
3.10 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Envelope glycoprotein
Chain IDs:B (auth: A), C (auth: B), D (auth: C)
Chain Length:706
Number of Molecules:3
Biological Source:Ebola virus
Polymer Type:polypeptide(L)
Description:Nanosota-EB2
Chain IDs:A (auth: D), E, F
Chain Length:144
Number of Molecules:3
Biological Source:Vicugna pacos
Ligand Molecules
Primary Citation
Discovery of Nanosota-EB1 and -EB2 as Novel Nanobody Inhibitors Against Ebola Virus Infection.
Plos Pathog. 20 e1012817 e1012817 (2024)
PMID: 39715280 DOI: 10.1371/journal.ppat.1012817

Abstact

The Ebola filovirus (EBOV) poses a serious threat to global health and national security. Nanobodies, a type of single-domain antibody, have demonstrated promising therapeutic potential. We identified two anti-EBOV nanobodies, Nanosota-EB1 and Nanosota-EB2, which specifically target the EBOV glycoprotein (GP). Cryo-EM and biochemical data revealed that Nanosota-EB1 binds to the glycan cap of GP1, preventing its protease cleavage, while Nanosota-EB2 binds to critical membrane-fusion elements in GP2, stabilizing it in the pre-fusion state. Nanosota-EB2 is a potent neutralizer of EBOV infection in vitro and offers excellent protection in a mouse model of EBOV challenge, while Nanosota-EB1 provides moderate neutralization and protection. Nanosota-EB1 and Nanosota-EB2 are the first nanobodies shown to inhibit authentic EBOV. Combined with our newly developed structure-guided in vitro evolution approach, they lay the foundation for nanobody-based therapies against EBOV and other viruses within the ebolavirus genus.

Legend

Protein

Chemical

Disease

Primary Citation of related structures